T2 Biosystems Inc
NASDAQ:TTOO
Operating Margin
T2 Biosystems Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
T2 Biosystems Inc
NASDAQ:TTOO
|
420.8k USD |
-543%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
337.9B USD |
30%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.8B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
141.4B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.9B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
T2 Biosystems Inc
Glance View
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 182 full-time employees. The company went IPO on 2014-08-07. The firm is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The firm is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common blood stream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on T2 Biosystems Inc's most recent financial statements, the company has Operating Margin of -542.6%.
You don't have any saved screeners yet